Floatz logo

(+)-VINCRISTINE

Endocrine System Diseases

Xiaoxiang ChenSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Endocrine System Diseases cohort.

Asset / SponsorPhaseRating
Hcg
Merck KGaA, Darmstadt, Germany
Phase 3BB
Irinotecan
Xiaoxiang Chen
Phase 2BB
Letrozole
Assiut University
Phase 2B
Metformin
Assiut University
Phase 2B
GSK-2256294A
Vanderbilt University Medical Center
Phase 2B

View all 22 →

Same molecule, other indications

(+)-VINCRISTINE is also rated in:

anaplastic large cell lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →